STOCK TITAN

Seer to Present at the J.P. Morgan 41st Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Seer, Inc. (Nasdaq: SEER) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. Management will present at 3:00 p.m. PT / 6:00 p.m. ET, followed by a Q&A session. Investors can access a live webcast on the Investor section of Seer's website, with an archived replay available afterwards.

Seer specializes in proteomics, offering the Proteograph™ Product Suite, a unique solution for deep proteomic analysis. For further details, visit www.seer.bio.

Positive
  • None.
Negative
  • None.

REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Seer’s management is scheduled to present and participate in a Q&A session on Tuesday, January 10th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio


FAQ

When is Seer Inc.'s presentation at the 41st Annual J.P. Morgan Healthcare Conference?

Seer Inc. will present on January 10, 2023, at 3:00 p.m. Pacific Time.

How can I watch Seer Inc.'s presentation at the J.P. Morgan Healthcare Conference?

You can watch the live webcast on Seer's Investor website, with an archived replay available later.

What product does Seer Inc. specialize in?

Seer Inc. specializes in the Proteograph™ Product Suite, focused on proteomic analysis.

Is the Proteograph™ Product Suite intended for diagnostic procedures?

No, the Proteograph™ Product Suite is for research use only and not intended for diagnostic procedures.

What are the key features of Seer Inc.'s Proteograph™ Product Suite?

The Proteograph™ Product Suite includes engineered nanoparticles, consumables, and software for deep proteomic analysis at scale.

Seer, Inc.

NASDAQ:SEER

SEER Rankings

SEER Latest News

SEER Stock Data

135.33M
54.92M
4.76%
68.86%
1.22%
Biotechnology
Laboratory Analytical Instruments
Link
United States of America
REDWOOD CITY